Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy

Joint Authors

Christoforidis, John Byron
Agrawal, Shivi
Joshi, Malav

Source

Mediators of Inflammation

Issue

Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-6, 6 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2013-11-06

Country of Publication

Egypt

No. of Pages

6

Main Subjects

Diseases

Abstract EN

Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes.

Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases.

Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept.

The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance.

This paper focuses on sterile endophthalmitis.

In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.

American Psychological Association (APA)

Agrawal, Shivi& Joshi, Malav& Christoforidis, John Byron. 2013. Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. Mediators of Inflammation،Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-510197

Modern Language Association (MLA)

Agrawal, Shivi…[et al.]. Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. Mediators of Inflammation No. 2013 (2013), pp.1-6.
https://search.emarefa.net/detail/BIM-510197

American Medical Association (AMA)

Agrawal, Shivi& Joshi, Malav& Christoforidis, John Byron. Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. Mediators of Inflammation. 2013. Vol. 2013, no. 2013, pp.1-6.
https://search.emarefa.net/detail/BIM-510197

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-510197